Proceeds will provide education and outreach about clinical research participation to patients and their families in minority and under-served communities
The Center for Information and Study on Clinical Research Participation (CISCRP), a Boston-based nonprofit organization, will be hosting its Medical Heroes Appreciation 5K Run & Walk in conjunction with the Drug Information Association (DIA) at the DIA 2019 Global Annual Meeting on June 24, in San Diego. The annual 5K salutes the millions of “Medical Heroes” who have given the gift of participating in clinical trials.
While CISCRP now hosts many such events across the country and virtually, the organization first conceived the idea for the Medical Heroes Appreciation 5K in October 2013. The DIA quickly stepped up, and at their Global Meeting in June 2014, became the first entity to host the event. Since then, thousands of runners and walkers have taken part in Med Hero events to show their support and appreciation.
“We understand the importance of clinical research volunteers and are proud to support CISCRP’s mission during the DIA 2019 Global Annual Meeting in San Diego. We know that so many of our attendees look forward to this early morning 5K, and it is our hope that DIA 2019 attendees will continue to participate in this event to honor Medical Heroes and raise awareness for clinical research,” says Sudip S. Parikh, PhD, Senior Vice President and Managing Director, DIA Americas.
Hundreds of attendees from DIA 2019 are expected to participate, along with members of the local San Diego public. CISCRP also accepts “virtual runners and walkers,” who are unable to attend in person. These participants register online and then run or walk in a location of their choosing.
In addition to the trek around the harborside course, CISCRP is providing educational health resources and a free breakfast. The event is greatly made possible with Olympiad-Level Sponsorship by WCG.
“We are tremendously thankful for WCG’s contribution to making our Med Hero Appreciation 5K possible,” says Ellyn Getz, Associate Director, Development & Community Engagement at CISCRP. “WCG has helped us in the past and continues to be a strong supporter of improving clinical research literacy and celebrating those who participate in clinical trials.”
Says Donald A. Deieso, Ph.D., Executive Chairman and Chief Executive Officer of WCG, “Without the many volunteers who take part in clinical trials, we would not have the life-saving medicines we have today. CISCRP’s Med Hero 5K affords us the opportunity to recognize and celebrate their extraordinary contribution to the future of human health.”
CISCRP’s Medical Heroes Appreciation 5K will be held on Monday, June 24, 6:30 a.m. to 7:30 a.m. To register, https://medhero5ksd19.eventbrite.com/?aff=actenewsletter
For additional information, go to www.ciscrp.org, email medheroevents@ciscrp.org
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.